Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HKP-siRNA-PMEPA1
- Development stage
- Preclinical
- Lead developer
- Sirnaomics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation, Intranasal
01
Overview
HKP-siRNA-PMEPA1 is an experimental RNA interference (RNAi) therapeutic consisting of a small interfering RNA (siRNA) targeting the Prostate Transmembrane Protein, Androgen Induced 1 (PMEPA1) mRNA, encapsulated within a Histidine-Lysine Polymer (HKP) nanoparticle delivery system. Developed by Sirnaomics, this drug candidate utilizes the proprietary HKP platform to protect the siRNA from degradation and facilitate its entry into target cells. PMEPA1 is a key regulator of the Transforming Growth Factor-beta (TGF-β) signaling pathway and is implicated in mitochondrial dysfunction, mitophagy dysregulation, and pathological phenotype shifts in airway structural cells. By silencing PMEPA1 expression, the therapy aims to inhibit airway remodeling and chronic inflammation, particularly in the context of therapeutic-resistant asthma and other fibrotic conditions.
- Other names
- HKP-PMEPA1-siRNAHKP-PMEPA-1-siRNAHKP-PMEPA 1-siRNAsiRNA-PMEPA1siRNA-PMEPA-1siRNA-PMEPA 1
02
Targets
PMEPA1 (Prostate transmembrane protein, androgen induced 1)
Beyond the preview
Go deeper on HKP-siRNA-PMEPA1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HKP-siRNA-PMEPA1.